~~<i id='B3BA5749D7'><strike id='B3BA5749D7'><tt id='B3BA5749D7'><pre id='B3BA5749D7'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

comprehensive

author：hotspot 2025-09-29 01:06:25 - browse：934

A European regulatory panel has recommended against approval of a lung cancer drug made by Mirati Therapeutics, the company said Friday.

Mirati said it will appeal the negative opinion of the drug, called Krazati, issued by a committee of the European Medicines Agency that met this week. But for now, the adverse decision is likely to be adopted by European regulators and prevent the company from marketing the pill in Europe.

Krazati works by blocking a specific type of KRAS alteration called G12C, found in approximately 13% of lung tumors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Readout Newsletter: Merck, Vertex, and Viking updates

focus

leisure time

knowledge

Wikipedia

focus

entertainment

Somearguethattakingmethadoneathomeisfarbetterthantrudgingtoacliniceveryday.KevinD.Liles/APSincetheFo

WSS

Donor acceptance rates hint at racial, gender bias in heart transplants: study

Lessons Learned: This is why you network to find that industry job you want

Biden praises World Series champion Astros for impact off the field during White House celebration

There's no autism epidemic. It's an autism diagnosis epidemic

Readout LOUD podcast: mifepristone case, GLP

Biden praises World Series champion Astros for impact off the field during White House celebration

knowledge

comprehensive

focus

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Why the world’s most expensive drug might be worth the price

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

An Ebola outbreak presents a new mystery involving children

Walensky prepares to leave CDC — and Congress — behind

Patient advocates debate FDA's accelerated approval process

State Dept. review finds Biden bears some blame for Afghanistan failures

A year after a Russian missile took her leg, a young Ukrainian gymnast's spirit endures

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Hospitals use virtual reality to design more inclusive rooms for kids

leisure time

There's no autism epidemic. It's an autism diagnosis epidemic

Covid vaccine financial winners and losers, from Pfizer to Novavax

States should stop sabotaging methadone treatment reform

Choosing scientific sides in the fight against Alzheimer's

Oprah kicked off a national conversation on obesity. Let's have it

Judge rejects Trump's counterclaim against E. Jean Carroll

knowledge

Wikipedia

focus

entertainment